Global Vector-Based RNAi Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Vector-based RNAi (RNA interference) offers a system of treatment and disease management to decrease the inhibition of gene translation or expression, as well as it neutralizes the targeted mRNA molecules. Vector-based RNAi plays very important in cancer treatment,cancer is the top second cause of death across the globe. As well as a new development in vector-based RNAi such as small interfering RNAs (siRNA) and microRNAs (miRNA) can escalate the vector-based RNAi market growth. The challenging situation of FDA approval affecting on a number of new drugs launch, for instance, 2015 (41 drugs), while in 2016 (19 drugs) which are very less as compared with the previous year.
LPI (LP Information)' newest research report, the “Vector-Based RNAi Industry Forecast” looks at past sales and reviews total world Vector-Based RNAi sales in 2022, providing a comprehensive analysis by region and market sector of projected Vector-Based RNAi sales for 2023 through 2029. With Vector-Based RNAi sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vector-Based RNAi industry.
This Insight Report provides a comprehensive analysis of the global Vector-Based RNAi landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vector-Based RNAi portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vector-Based RNAi market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vector-Based RNAi and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vector-Based RNAi.
The global Vector-Based RNAi market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Vector-Based RNAi is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Vector-Based RNAi is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Vector-Based RNAi is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Vector-Based RNAi players cover Merck & Co., Phio Pharmaceutical, Quark Pharmaceuticals, Thermo Fisher Scientific, Silence Therapeutics, Qiagen NV, Ionis Pharmaceutical, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Vector-Based RNAi market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Vector-Based RNAi market?
What factors are driving Vector-Based RNAi market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vector-Based RNAi market opportunities vary by end market size?
How does Vector-Based RNAi break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Vector-based RNAi (RNA interference) offers a system of treatment and disease management to decrease the inhibition of gene translation or expression, as well as it neutralizes the targeted mRNA molecules. Vector-based RNAi plays very important in cancer treatment,cancer is the top second cause of death across the globe. As well as a new development in vector-based RNAi such as small interfering RNAs (siRNA) and microRNAs (miRNA) can escalate the vector-based RNAi market growth. The challenging situation of FDA approval affecting on a number of new drugs launch, for instance, 2015 (41 drugs), while in 2016 (19 drugs) which are very less as compared with the previous year.
LPI (LP Information)' newest research report, the “Vector-Based RNAi Industry Forecast” looks at past sales and reviews total world Vector-Based RNAi sales in 2022, providing a comprehensive analysis by region and market sector of projected Vector-Based RNAi sales for 2023 through 2029. With Vector-Based RNAi sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vector-Based RNAi industry.
This Insight Report provides a comprehensive analysis of the global Vector-Based RNAi landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vector-Based RNAi portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vector-Based RNAi market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vector-Based RNAi and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vector-Based RNAi.
The global Vector-Based RNAi market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Vector-Based RNAi is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Vector-Based RNAi is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Vector-Based RNAi is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Vector-Based RNAi players cover Merck & Co., Phio Pharmaceutical, Quark Pharmaceuticals, Thermo Fisher Scientific, Silence Therapeutics, Qiagen NV, Ionis Pharmaceutical, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Vector-Based RNAi market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- siRNA Design
- siRNA Vectors
- Custom siRNA Construction
- Hospitals
- Speciality Clinics
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck & Co.
- Phio Pharmaceutical
- Quark Pharmaceuticals
- Thermo Fisher Scientific
- Silence Therapeutics
- Qiagen NV
- Ionis Pharmaceutical
- Dicerna Pharmaceuticals
- Arrowhead Pharmaceuticals
- Arcturus Therapeutics
- Alnylam Pharmaceuticals
What is the 10-year outlook for the global Vector-Based RNAi market?
What factors are driving Vector-Based RNAi market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vector-Based RNAi market opportunities vary by end market size?
How does Vector-Based RNAi break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vector-Based RNAi Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Vector-Based RNAi by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Vector-Based RNAi by Country/Region, 2018, 2022 & 2029
2.2 Vector-Based RNAi Segment by Type
2.2.1 siRNA Design
2.2.2 siRNA Vectors
2.2.3 Custom siRNA Construction
2.3 Vector-Based RNAi Sales by Type
2.3.1 Global Vector-Based RNAi Sales Market Share by Type (2018-2023)
2.3.2 Global Vector-Based RNAi Revenue and Market Share by Type (2018-2023)
2.3.3 Global Vector-Based RNAi Sale Price by Type (2018-2023)
2.4 Vector-Based RNAi Segment by Application
2.4.1 Hospitals
2.4.2 Speciality Clinics
2.5 Vector-Based RNAi Sales by Application
2.5.1 Global Vector-Based RNAi Sale Market Share by Application (2018-2023)
2.5.2 Global Vector-Based RNAi Revenue and Market Share by Application (2018-2023)
2.5.3 Global Vector-Based RNAi Sale Price by Application (2018-2023)
3 GLOBAL VECTOR-BASED RNAI BY COMPANY
3.1 Global Vector-Based RNAi Breakdown Data by Company
3.1.1 Global Vector-Based RNAi Annual Sales by Company (2018-2023)
3.1.2 Global Vector-Based RNAi Sales Market Share by Company (2018-2023)
3.2 Global Vector-Based RNAi Annual Revenue by Company (2018-2023)
3.2.1 Global Vector-Based RNAi Revenue by Company (2018-2023)
3.2.2 Global Vector-Based RNAi Revenue Market Share by Company (2018-2023)
3.3 Global Vector-Based RNAi Sale Price by Company
3.4 Key Manufacturers Vector-Based RNAi Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vector-Based RNAi Product Location Distribution
3.4.2 Players Vector-Based RNAi Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VECTOR-BASED RNAI BY GEOGRAPHIC REGION
4.1 World Historic Vector-Based RNAi Market Size by Geographic Region (2018-2023)
4.1.1 Global Vector-Based RNAi Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Vector-Based RNAi Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Vector-Based RNAi Market Size by Country/Region (2018-2023)
4.2.1 Global Vector-Based RNAi Annual Sales by Country/Region (2018-2023)
4.2.2 Global Vector-Based RNAi Annual Revenue by Country/Region (2018-2023)
4.3 Americas Vector-Based RNAi Sales Growth
4.4 APAC Vector-Based RNAi Sales Growth
4.5 Europe Vector-Based RNAi Sales Growth
4.6 Middle East & Africa Vector-Based RNAi Sales Growth
5 AMERICAS
5.1 Americas Vector-Based RNAi Sales by Country
5.1.1 Americas Vector-Based RNAi Sales by Country (2018-2023)
5.1.2 Americas Vector-Based RNAi Revenue by Country (2018-2023)
5.2 Americas Vector-Based RNAi Sales by Type
5.3 Americas Vector-Based RNAi Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vector-Based RNAi Sales by Region
6.1.1 APAC Vector-Based RNAi Sales by Region (2018-2023)
6.1.2 APAC Vector-Based RNAi Revenue by Region (2018-2023)
6.2 APAC Vector-Based RNAi Sales by Type
6.3 APAC Vector-Based RNAi Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vector-Based RNAi by Country
7.1.1 Europe Vector-Based RNAi Sales by Country (2018-2023)
7.1.2 Europe Vector-Based RNAi Revenue by Country (2018-2023)
7.2 Europe Vector-Based RNAi Sales by Type
7.3 Europe Vector-Based RNAi Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vector-Based RNAi by Country
8.1.1 Middle East & Africa Vector-Based RNAi Sales by Country (2018-2023)
8.1.2 Middle East & Africa Vector-Based RNAi Revenue by Country (2018-2023)
8.2 Middle East & Africa Vector-Based RNAi Sales by Type
8.3 Middle East & Africa Vector-Based RNAi Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vector-Based RNAi
10.3 Manufacturing Process Analysis of Vector-Based RNAi
10.4 Industry Chain Structure of Vector-Based RNAi
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vector-Based RNAi Distributors
11.3 Vector-Based RNAi Customer
12 WORLD FORECAST REVIEW FOR VECTOR-BASED RNAI BY GEOGRAPHIC REGION
12.1 Global Vector-Based RNAi Market Size Forecast by Region
12.1.1 Global Vector-Based RNAi Forecast by Region (2024-2029)
12.1.2 Global Vector-Based RNAi Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Vector-Based RNAi Forecast by Type
12.7 Global Vector-Based RNAi Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co.
13.1.1 Merck & Co. Company Information
13.1.2 Merck & Co. Vector-Based RNAi Product Portfolios and Specifications
13.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck & Co. Main Business Overview
13.1.5 Merck & Co. Latest Developments
13.2 Phio Pharmaceutical
13.2.1 Phio Pharmaceutical Company Information
13.2.2 Phio Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
13.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Phio Pharmaceutical Main Business Overview
13.2.5 Phio Pharmaceutical Latest Developments
13.3 Quark Pharmaceuticals
13.3.1 Quark Pharmaceuticals Company Information
13.3.2 Quark Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Quark Pharmaceuticals Main Business Overview
13.3.5 Quark Pharmaceuticals Latest Developments
13.4 Thermo Fisher Scientific
13.4.1 Thermo Fisher Scientific Company Information
13.4.2 Thermo Fisher Scientific Vector-Based RNAi Product Portfolios and Specifications
13.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Thermo Fisher Scientific Main Business Overview
13.4.5 Thermo Fisher Scientific Latest Developments
13.5 Silence Therapeutics
13.5.1 Silence Therapeutics Company Information
13.5.2 Silence Therapeutics Vector-Based RNAi Product Portfolios and Specifications
13.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Silence Therapeutics Main Business Overview
13.5.5 Silence Therapeutics Latest Developments
13.6 Qiagen NV
13.6.1 Qiagen NV Company Information
13.6.2 Qiagen NV Vector-Based RNAi Product Portfolios and Specifications
13.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Qiagen NV Main Business Overview
13.6.5 Qiagen NV Latest Developments
13.7 Ionis Pharmaceutical
13.7.1 Ionis Pharmaceutical Company Information
13.7.2 Ionis Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
13.7.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Ionis Pharmaceutical Main Business Overview
13.7.5 Ionis Pharmaceutical Latest Developments
13.8 Dicerna Pharmaceuticals
13.8.1 Dicerna Pharmaceuticals Company Information
13.8.2 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Dicerna Pharmaceuticals Main Business Overview
13.8.5 Dicerna Pharmaceuticals Latest Developments
13.9 Arrowhead Pharmaceuticals
13.9.1 Arrowhead Pharmaceuticals Company Information
13.9.2 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Arrowhead Pharmaceuticals Main Business Overview
13.9.5 Arrowhead Pharmaceuticals Latest Developments
13.10 Arcturus Therapeutics
13.10.1 Arcturus Therapeutics Company Information
13.10.2 Arcturus Therapeutics Vector-Based RNAi Product Portfolios and Specifications
13.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Arcturus Therapeutics Main Business Overview
13.10.5 Arcturus Therapeutics Latest Developments
13.11 Alnylam Pharmaceuticals
13.11.1 Alnylam Pharmaceuticals Company Information
13.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Alnylam Pharmaceuticals Main Business Overview
13.11.5 Alnylam Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vector-Based RNAi Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Vector-Based RNAi by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Vector-Based RNAi by Country/Region, 2018, 2022 & 2029
2.2 Vector-Based RNAi Segment by Type
2.2.1 siRNA Design
2.2.2 siRNA Vectors
2.2.3 Custom siRNA Construction
2.3 Vector-Based RNAi Sales by Type
2.3.1 Global Vector-Based RNAi Sales Market Share by Type (2018-2023)
2.3.2 Global Vector-Based RNAi Revenue and Market Share by Type (2018-2023)
2.3.3 Global Vector-Based RNAi Sale Price by Type (2018-2023)
2.4 Vector-Based RNAi Segment by Application
2.4.1 Hospitals
2.4.2 Speciality Clinics
2.5 Vector-Based RNAi Sales by Application
2.5.1 Global Vector-Based RNAi Sale Market Share by Application (2018-2023)
2.5.2 Global Vector-Based RNAi Revenue and Market Share by Application (2018-2023)
2.5.3 Global Vector-Based RNAi Sale Price by Application (2018-2023)
3 GLOBAL VECTOR-BASED RNAI BY COMPANY
3.1 Global Vector-Based RNAi Breakdown Data by Company
3.1.1 Global Vector-Based RNAi Annual Sales by Company (2018-2023)
3.1.2 Global Vector-Based RNAi Sales Market Share by Company (2018-2023)
3.2 Global Vector-Based RNAi Annual Revenue by Company (2018-2023)
3.2.1 Global Vector-Based RNAi Revenue by Company (2018-2023)
3.2.2 Global Vector-Based RNAi Revenue Market Share by Company (2018-2023)
3.3 Global Vector-Based RNAi Sale Price by Company
3.4 Key Manufacturers Vector-Based RNAi Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vector-Based RNAi Product Location Distribution
3.4.2 Players Vector-Based RNAi Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VECTOR-BASED RNAI BY GEOGRAPHIC REGION
4.1 World Historic Vector-Based RNAi Market Size by Geographic Region (2018-2023)
4.1.1 Global Vector-Based RNAi Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Vector-Based RNAi Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Vector-Based RNAi Market Size by Country/Region (2018-2023)
4.2.1 Global Vector-Based RNAi Annual Sales by Country/Region (2018-2023)
4.2.2 Global Vector-Based RNAi Annual Revenue by Country/Region (2018-2023)
4.3 Americas Vector-Based RNAi Sales Growth
4.4 APAC Vector-Based RNAi Sales Growth
4.5 Europe Vector-Based RNAi Sales Growth
4.6 Middle East & Africa Vector-Based RNAi Sales Growth
5 AMERICAS
5.1 Americas Vector-Based RNAi Sales by Country
5.1.1 Americas Vector-Based RNAi Sales by Country (2018-2023)
5.1.2 Americas Vector-Based RNAi Revenue by Country (2018-2023)
5.2 Americas Vector-Based RNAi Sales by Type
5.3 Americas Vector-Based RNAi Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vector-Based RNAi Sales by Region
6.1.1 APAC Vector-Based RNAi Sales by Region (2018-2023)
6.1.2 APAC Vector-Based RNAi Revenue by Region (2018-2023)
6.2 APAC Vector-Based RNAi Sales by Type
6.3 APAC Vector-Based RNAi Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vector-Based RNAi by Country
7.1.1 Europe Vector-Based RNAi Sales by Country (2018-2023)
7.1.2 Europe Vector-Based RNAi Revenue by Country (2018-2023)
7.2 Europe Vector-Based RNAi Sales by Type
7.3 Europe Vector-Based RNAi Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vector-Based RNAi by Country
8.1.1 Middle East & Africa Vector-Based RNAi Sales by Country (2018-2023)
8.1.2 Middle East & Africa Vector-Based RNAi Revenue by Country (2018-2023)
8.2 Middle East & Africa Vector-Based RNAi Sales by Type
8.3 Middle East & Africa Vector-Based RNAi Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vector-Based RNAi
10.3 Manufacturing Process Analysis of Vector-Based RNAi
10.4 Industry Chain Structure of Vector-Based RNAi
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vector-Based RNAi Distributors
11.3 Vector-Based RNAi Customer
12 WORLD FORECAST REVIEW FOR VECTOR-BASED RNAI BY GEOGRAPHIC REGION
12.1 Global Vector-Based RNAi Market Size Forecast by Region
12.1.1 Global Vector-Based RNAi Forecast by Region (2024-2029)
12.1.2 Global Vector-Based RNAi Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Vector-Based RNAi Forecast by Type
12.7 Global Vector-Based RNAi Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Merck & Co.
13.1.1 Merck & Co. Company Information
13.1.2 Merck & Co. Vector-Based RNAi Product Portfolios and Specifications
13.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck & Co. Main Business Overview
13.1.5 Merck & Co. Latest Developments
13.2 Phio Pharmaceutical
13.2.1 Phio Pharmaceutical Company Information
13.2.2 Phio Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
13.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Phio Pharmaceutical Main Business Overview
13.2.5 Phio Pharmaceutical Latest Developments
13.3 Quark Pharmaceuticals
13.3.1 Quark Pharmaceuticals Company Information
13.3.2 Quark Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Quark Pharmaceuticals Main Business Overview
13.3.5 Quark Pharmaceuticals Latest Developments
13.4 Thermo Fisher Scientific
13.4.1 Thermo Fisher Scientific Company Information
13.4.2 Thermo Fisher Scientific Vector-Based RNAi Product Portfolios and Specifications
13.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Thermo Fisher Scientific Main Business Overview
13.4.5 Thermo Fisher Scientific Latest Developments
13.5 Silence Therapeutics
13.5.1 Silence Therapeutics Company Information
13.5.2 Silence Therapeutics Vector-Based RNAi Product Portfolios and Specifications
13.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Silence Therapeutics Main Business Overview
13.5.5 Silence Therapeutics Latest Developments
13.6 Qiagen NV
13.6.1 Qiagen NV Company Information
13.6.2 Qiagen NV Vector-Based RNAi Product Portfolios and Specifications
13.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Qiagen NV Main Business Overview
13.6.5 Qiagen NV Latest Developments
13.7 Ionis Pharmaceutical
13.7.1 Ionis Pharmaceutical Company Information
13.7.2 Ionis Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
13.7.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Ionis Pharmaceutical Main Business Overview
13.7.5 Ionis Pharmaceutical Latest Developments
13.8 Dicerna Pharmaceuticals
13.8.1 Dicerna Pharmaceuticals Company Information
13.8.2 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Dicerna Pharmaceuticals Main Business Overview
13.8.5 Dicerna Pharmaceuticals Latest Developments
13.9 Arrowhead Pharmaceuticals
13.9.1 Arrowhead Pharmaceuticals Company Information
13.9.2 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Arrowhead Pharmaceuticals Main Business Overview
13.9.5 Arrowhead Pharmaceuticals Latest Developments
13.10 Arcturus Therapeutics
13.10.1 Arcturus Therapeutics Company Information
13.10.2 Arcturus Therapeutics Vector-Based RNAi Product Portfolios and Specifications
13.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Arcturus Therapeutics Main Business Overview
13.10.5 Arcturus Therapeutics Latest Developments
13.11 Alnylam Pharmaceuticals
13.11.1 Alnylam Pharmaceuticals Company Information
13.11.2 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
13.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Alnylam Pharmaceuticals Main Business Overview
13.11.5 Alnylam Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Vector-Based RNAi Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Vector-Based RNAi Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of siRNA Design
Table 4. Major Players of siRNA Vectors
Table 5. Major Players of Custom siRNA Construction
Table 6. Global Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 7. Global Vector-Based RNAi Sales Market Share by Type (2018-2023)
Table 8. Global Vector-Based RNAi Revenue by Type (2018-2023) & ($ million)
Table 9. Global Vector-Based RNAi Revenue Market Share by Type (2018-2023)
Table 10. Global Vector-Based RNAi Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 12. Global Vector-Based RNAi Sales Market Share by Application (2018-2023)
Table 13. Global Vector-Based RNAi Revenue by Application (2018-2023)
Table 14. Global Vector-Based RNAi Revenue Market Share by Application (2018-2023)
Table 15. Global Vector-Based RNAi Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Vector-Based RNAi Sales by Company (2018-2023) & (K Units)
Table 17. Global Vector-Based RNAi Sales Market Share by Company (2018-2023)
Table 18. Global Vector-Based RNAi Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Vector-Based RNAi Revenue Market Share by Company (2018-2023)
Table 20. Global Vector-Based RNAi Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Vector-Based RNAi Producing Area Distribution and Sales Area
Table 22. Players Vector-Based RNAi Products Offered
Table 23. Vector-Based RNAi Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Vector-Based RNAi Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Vector-Based RNAi Sales Market Share Geographic Region (2018-2023)
Table 28. Global Vector-Based RNAi Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Vector-Based RNAi Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Vector-Based RNAi Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Vector-Based RNAi Sales Market Share by Country/Region (2018-2023)
Table 32. Global Vector-Based RNAi Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Vector-Based RNAi Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Vector-Based RNAi Sales by Country (2018-2023) & (K Units)
Table 35. Americas Vector-Based RNAi Sales Market Share by Country (2018-2023)
Table 36. Americas Vector-Based RNAi Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Vector-Based RNAi Revenue Market Share by Country (2018-2023)
Table 38. Americas Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 39. Americas Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 40. APAC Vector-Based RNAi Sales by Region (2018-2023) & (K Units)
Table 41. APAC Vector-Based RNAi Sales Market Share by Region (2018-2023)
Table 42. APAC Vector-Based RNAi Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Vector-Based RNAi Revenue Market Share by Region (2018-2023)
Table 44. APAC Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 45. APAC Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 46. Europe Vector-Based RNAi Sales by Country (2018-2023) & (K Units)
Table 47. Europe Vector-Based RNAi Sales Market Share by Country (2018-2023)
Table 48. Europe Vector-Based RNAi Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Vector-Based RNAi Revenue Market Share by Country (2018-2023)
Table 50. Europe Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 51. Europe Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Vector-Based RNAi Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Vector-Based RNAi Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Vector-Based RNAi Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Vector-Based RNAi Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Vector-Based RNAi
Table 59. Key Market Challenges & Risks of Vector-Based RNAi
Table 60. Key Industry Trends of Vector-Based RNAi
Table 61. Vector-Based RNAi Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Vector-Based RNAi Distributors List
Table 64. Vector-Based RNAi Customer List
Table 65. Global Vector-Based RNAi Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Vector-Based RNAi Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Vector-Based RNAi Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Vector-Based RNAi Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Vector-Based RNAi Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Vector-Based RNAi Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Vector-Based RNAi Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Vector-Based RNAi Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Vector-Based RNAi Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Vector-Based RNAi Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Vector-Based RNAi Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Merck & Co. Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 80. Merck & Co. Vector-Based RNAi Product Portfolios and Specifications
Table 81. Merck & Co. Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Merck & Co. Main Business
Table 83. Merck & Co. Latest Developments
Table 84. Phio Pharmaceutical Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 85. Phio Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
Table 86. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Phio Pharmaceutical Main Business
Table 88. Phio Pharmaceutical Latest Developments
Table 89. Quark Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 90. Quark Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 91. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Quark Pharmaceuticals Main Business
Table 93. Quark Pharmaceuticals Latest Developments
Table 94. Thermo Fisher Scientific Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 95. Thermo Fisher Scientific Vector-Based RNAi Product Portfolios and Specifications
Table 96. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Thermo Fisher Scientific Main Business
Table 98. Thermo Fisher Scientific Latest Developments
Table 99. Silence Therapeutics Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 100. Silence Therapeutics Vector-Based RNAi Product Portfolios and Specifications
Table 101. Silence Therapeutics Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Silence Therapeutics Main Business
Table 103. Silence Therapeutics Latest Developments
Table 104. Qiagen NV Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 105. Qiagen NV Vector-Based RNAi Product Portfolios and Specifications
Table 106. Qiagen NV Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Qiagen NV Main Business
Table 108. Qiagen NV Latest Developments
Table 109. Ionis Pharmaceutical Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 110. Ionis Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
Table 111. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Ionis Pharmaceutical Main Business
Table 113. Ionis Pharmaceutical Latest Developments
Table 114. Dicerna Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 115. Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 116. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Dicerna Pharmaceuticals Main Business
Table 118. Dicerna Pharmaceuticals Latest Developments
Table 119. Arrowhead Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 120. Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 121. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Arrowhead Pharmaceuticals Main Business
Table 123. Arrowhead Pharmaceuticals Latest Developments
Table 124. Arcturus Therapeutics Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 125. Arcturus Therapeutics Vector-Based RNAi Product Portfolios and Specifications
Table 126. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Arcturus Therapeutics Main Business
Table 128. Arcturus Therapeutics Latest Developments
Table 129. Alnylam Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 130. Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 131. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Alnylam Pharmaceuticals Main Business
Table 133. Alnylam Pharmaceuticals Latest Developments
Table 1. Vector-Based RNAi Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Vector-Based RNAi Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of siRNA Design
Table 4. Major Players of siRNA Vectors
Table 5. Major Players of Custom siRNA Construction
Table 6. Global Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 7. Global Vector-Based RNAi Sales Market Share by Type (2018-2023)
Table 8. Global Vector-Based RNAi Revenue by Type (2018-2023) & ($ million)
Table 9. Global Vector-Based RNAi Revenue Market Share by Type (2018-2023)
Table 10. Global Vector-Based RNAi Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 12. Global Vector-Based RNAi Sales Market Share by Application (2018-2023)
Table 13. Global Vector-Based RNAi Revenue by Application (2018-2023)
Table 14. Global Vector-Based RNAi Revenue Market Share by Application (2018-2023)
Table 15. Global Vector-Based RNAi Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Vector-Based RNAi Sales by Company (2018-2023) & (K Units)
Table 17. Global Vector-Based RNAi Sales Market Share by Company (2018-2023)
Table 18. Global Vector-Based RNAi Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Vector-Based RNAi Revenue Market Share by Company (2018-2023)
Table 20. Global Vector-Based RNAi Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Vector-Based RNAi Producing Area Distribution and Sales Area
Table 22. Players Vector-Based RNAi Products Offered
Table 23. Vector-Based RNAi Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Vector-Based RNAi Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Vector-Based RNAi Sales Market Share Geographic Region (2018-2023)
Table 28. Global Vector-Based RNAi Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Vector-Based RNAi Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Vector-Based RNAi Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Vector-Based RNAi Sales Market Share by Country/Region (2018-2023)
Table 32. Global Vector-Based RNAi Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Vector-Based RNAi Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Vector-Based RNAi Sales by Country (2018-2023) & (K Units)
Table 35. Americas Vector-Based RNAi Sales Market Share by Country (2018-2023)
Table 36. Americas Vector-Based RNAi Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Vector-Based RNAi Revenue Market Share by Country (2018-2023)
Table 38. Americas Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 39. Americas Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 40. APAC Vector-Based RNAi Sales by Region (2018-2023) & (K Units)
Table 41. APAC Vector-Based RNAi Sales Market Share by Region (2018-2023)
Table 42. APAC Vector-Based RNAi Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Vector-Based RNAi Revenue Market Share by Region (2018-2023)
Table 44. APAC Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 45. APAC Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 46. Europe Vector-Based RNAi Sales by Country (2018-2023) & (K Units)
Table 47. Europe Vector-Based RNAi Sales Market Share by Country (2018-2023)
Table 48. Europe Vector-Based RNAi Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Vector-Based RNAi Revenue Market Share by Country (2018-2023)
Table 50. Europe Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 51. Europe Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Vector-Based RNAi Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Vector-Based RNAi Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Vector-Based RNAi Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Vector-Based RNAi Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Vector-Based RNAi Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Vector-Based RNAi Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Vector-Based RNAi
Table 59. Key Market Challenges & Risks of Vector-Based RNAi
Table 60. Key Industry Trends of Vector-Based RNAi
Table 61. Vector-Based RNAi Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Vector-Based RNAi Distributors List
Table 64. Vector-Based RNAi Customer List
Table 65. Global Vector-Based RNAi Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Vector-Based RNAi Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Vector-Based RNAi Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Vector-Based RNAi Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Vector-Based RNAi Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Vector-Based RNAi Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Vector-Based RNAi Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Vector-Based RNAi Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Vector-Based RNAi Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Vector-Based RNAi Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Vector-Based RNAi Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Vector-Based RNAi Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Merck & Co. Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 80. Merck & Co. Vector-Based RNAi Product Portfolios and Specifications
Table 81. Merck & Co. Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Merck & Co. Main Business
Table 83. Merck & Co. Latest Developments
Table 84. Phio Pharmaceutical Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 85. Phio Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
Table 86. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Phio Pharmaceutical Main Business
Table 88. Phio Pharmaceutical Latest Developments
Table 89. Quark Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 90. Quark Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 91. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Quark Pharmaceuticals Main Business
Table 93. Quark Pharmaceuticals Latest Developments
Table 94. Thermo Fisher Scientific Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 95. Thermo Fisher Scientific Vector-Based RNAi Product Portfolios and Specifications
Table 96. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Thermo Fisher Scientific Main Business
Table 98. Thermo Fisher Scientific Latest Developments
Table 99. Silence Therapeutics Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 100. Silence Therapeutics Vector-Based RNAi Product Portfolios and Specifications
Table 101. Silence Therapeutics Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Silence Therapeutics Main Business
Table 103. Silence Therapeutics Latest Developments
Table 104. Qiagen NV Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 105. Qiagen NV Vector-Based RNAi Product Portfolios and Specifications
Table 106. Qiagen NV Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Qiagen NV Main Business
Table 108. Qiagen NV Latest Developments
Table 109. Ionis Pharmaceutical Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 110. Ionis Pharmaceutical Vector-Based RNAi Product Portfolios and Specifications
Table 111. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Ionis Pharmaceutical Main Business
Table 113. Ionis Pharmaceutical Latest Developments
Table 114. Dicerna Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 115. Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 116. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Dicerna Pharmaceuticals Main Business
Table 118. Dicerna Pharmaceuticals Latest Developments
Table 119. Arrowhead Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 120. Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 121. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Arrowhead Pharmaceuticals Main Business
Table 123. Arrowhead Pharmaceuticals Latest Developments
Table 124. Arcturus Therapeutics Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 125. Arcturus Therapeutics Vector-Based RNAi Product Portfolios and Specifications
Table 126. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Arcturus Therapeutics Main Business
Table 128. Arcturus Therapeutics Latest Developments
Table 129. Alnylam Pharmaceuticals Basic Information, Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 130. Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolios and Specifications
Table 131. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Alnylam Pharmaceuticals Main Business
Table 133. Alnylam Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Vector-Based RNAi
Figure 2. Vector-Based RNAi Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vector-Based RNAi Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Vector-Based RNAi Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Vector-Based RNAi Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of siRNA Design
Figure 10. Product Picture of siRNA Vectors
Figure 11. Product Picture of Custom siRNA Construction
Figure 12. Global Vector-Based RNAi Sales Market Share by Type in 2022
Figure 13. Global Vector-Based RNAi Revenue Market Share by Type (2018-2023)
Figure 14. Vector-Based RNAi Consumed in Hospitals
Figure 15. Global Vector-Based RNAi Market: Hospitals (2018-2023) & (K Units)
Figure 16. Vector-Based RNAi Consumed in Speciality Clinics
Figure 17. Global Vector-Based RNAi Market: Speciality Clinics (2018-2023) & (K Units)
Figure 18. Global Vector-Based RNAi Sales Market Share by Application (2022)
Figure 19. Global Vector-Based RNAi Revenue Market Share by Application in 2022
Figure 20. Vector-Based RNAi Sales Market by Company in 2022 (K Units)
Figure 21. Global Vector-Based RNAi Sales Market Share by Company in 2022
Figure 22. Vector-Based RNAi Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Vector-Based RNAi Revenue Market Share by Company in 2022
Figure 24. Global Vector-Based RNAi Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Vector-Based RNAi Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 27. Americas Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 28. APAC Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 29. APAC Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 30. Europe Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 31. Europe Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 34. Americas Vector-Based RNAi Sales Market Share by Country in 2022
Figure 35. Americas Vector-Based RNAi Revenue Market Share by Country in 2022
Figure 36. Americas Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 37. Americas Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 38. United States Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Vector-Based RNAi Sales Market Share by Region in 2022
Figure 43. APAC Vector-Based RNAi Revenue Market Share by Regions in 2022
Figure 44. APAC Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 45. APAC Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 46. China Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Vector-Based RNAi Sales Market Share by Country in 2022
Figure 54. Europe Vector-Based RNAi Revenue Market Share by Country in 2022
Figure 55. Europe Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 56. Europe Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 57. Germany Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Vector-Based RNAi Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Vector-Based RNAi Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 66. Egypt Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Vector-Based RNAi in 2022
Figure 72. Manufacturing Process Analysis of Vector-Based RNAi
Figure 73. Industry Chain Structure of Vector-Based RNAi
Figure 74. Channels of Distribution
Figure 75. Global Vector-Based RNAi Sales Market Forecast by Region (2024-2029)
Figure 76. Global Vector-Based RNAi Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Vector-Based RNAi Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Vector-Based RNAi Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Vector-Based RNAi Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Vector-Based RNAi Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Vector-Based RNAi
Figure 2. Vector-Based RNAi Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vector-Based RNAi Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Vector-Based RNAi Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Vector-Based RNAi Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of siRNA Design
Figure 10. Product Picture of siRNA Vectors
Figure 11. Product Picture of Custom siRNA Construction
Figure 12. Global Vector-Based RNAi Sales Market Share by Type in 2022
Figure 13. Global Vector-Based RNAi Revenue Market Share by Type (2018-2023)
Figure 14. Vector-Based RNAi Consumed in Hospitals
Figure 15. Global Vector-Based RNAi Market: Hospitals (2018-2023) & (K Units)
Figure 16. Vector-Based RNAi Consumed in Speciality Clinics
Figure 17. Global Vector-Based RNAi Market: Speciality Clinics (2018-2023) & (K Units)
Figure 18. Global Vector-Based RNAi Sales Market Share by Application (2022)
Figure 19. Global Vector-Based RNAi Revenue Market Share by Application in 2022
Figure 20. Vector-Based RNAi Sales Market by Company in 2022 (K Units)
Figure 21. Global Vector-Based RNAi Sales Market Share by Company in 2022
Figure 22. Vector-Based RNAi Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Vector-Based RNAi Revenue Market Share by Company in 2022
Figure 24. Global Vector-Based RNAi Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Vector-Based RNAi Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 27. Americas Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 28. APAC Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 29. APAC Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 30. Europe Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 31. Europe Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Vector-Based RNAi Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Vector-Based RNAi Revenue 2018-2023 ($ Millions)
Figure 34. Americas Vector-Based RNAi Sales Market Share by Country in 2022
Figure 35. Americas Vector-Based RNAi Revenue Market Share by Country in 2022
Figure 36. Americas Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 37. Americas Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 38. United States Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Vector-Based RNAi Sales Market Share by Region in 2022
Figure 43. APAC Vector-Based RNAi Revenue Market Share by Regions in 2022
Figure 44. APAC Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 45. APAC Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 46. China Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Vector-Based RNAi Sales Market Share by Country in 2022
Figure 54. Europe Vector-Based RNAi Revenue Market Share by Country in 2022
Figure 55. Europe Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 56. Europe Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 57. Germany Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Vector-Based RNAi Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Vector-Based RNAi Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Vector-Based RNAi Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Vector-Based RNAi Sales Market Share by Application (2018-2023)
Figure 66. Egypt Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Vector-Based RNAi Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Vector-Based RNAi in 2022
Figure 72. Manufacturing Process Analysis of Vector-Based RNAi
Figure 73. Industry Chain Structure of Vector-Based RNAi
Figure 74. Channels of Distribution
Figure 75. Global Vector-Based RNAi Sales Market Forecast by Region (2024-2029)
Figure 76. Global Vector-Based RNAi Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Vector-Based RNAi Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Vector-Based RNAi Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Vector-Based RNAi Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Vector-Based RNAi Revenue Market Share Forecast by Application (2024-2029)
